Lorus Therapeutics Inc
LRUSF:OTCQB
| 最新 | 变化/%变化 | 股息收益率 | 交易量 | Avg Volume (10 day) |
| 0.277 | 0.00 0.00% | 0.00% | 0 | 243 |
市场数据至少延迟20分钟
Lorus Therapeutics Inc的最新新闻标题
No News for Lorus Therapeutics Inc
公司背景
Lorus Therapeutics Inc. (Lorus) is a biopharmaceutical company. The Company is a discovery, research and clinical development-stage company with a focus on cancer drugs. The Company has an active portfolio, including small molecules (LOR-253/LOR-500) and an immunotherapy (IL-17E). Lorus has worked to establish a marketable anticancer product pipeline, with products in various stages of development ranging from discovery and pre-clinical to a product available to start a Phase III clinical trial. Lorus has one subsidiary, NuChem Pharmaceuticals Inc. (NuChem).
买方价/量 -- / -- | 卖方价/量 -- / -- |
开盘价格 0.00 | 前收盘价格 0.277 |
当天最高 0.00 | 当天最低 0.00 |
52周高/日期 0.595 / 5/1/2012 | 52周低/日期 0.186 / 9/28/2012 |
% off 52wk High -53.45% | % off 52wk Low 48.92% |
贝他(5年) 1.5 | 市值 11.7M |
流通股数 42.3M | 波动平均(Volatility Avg) 0.00 |
每股收益(EPS)(TTM) -0.16 | 市盈率(P/E) Not Meaningful |
股息宣布日 -- | 股息收益率 0.00% |
除息日 -- | 登记日 -- |
支付数额 0.00 - -- | 支付日期 -- |
上次交易3/15/2013 10:50 AM ET | |
LRUSF Lorus Therapeutics Inc 对比同行
| 同行 | |
|---|---|
LRUSF Lorus Therapeutics Inc | -8.88% |
Celgene Corporation | 42.60% |
Biogen Idec Inc. | 19.92% |
ISIS Pharmaceuticals, Inc. | 68.87% |
Idera Pharmaceuticals Inc | -34.83% |
LRUSF Lorus Therapeutics Inc | 0.00% |
Celgene Corporation | -- |
Biogen Idec Inc. | -- |
ISIS Pharmaceuticals, Inc. | -- |
Idera Pharmaceuticals Inc | -- |
LRUSF Lorus Therapeutics Inc | 0.00% |
Celgene Corporation | 0.00% |
Biogen Idec Inc. | 0.00% |
ISIS Pharmaceuticals, Inc. | 0.00% |
Idera Pharmaceuticals Inc | 0.00% |